Cencora (COR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
22 Jan, 2026Executive summary
Annual meeting scheduled for March 5, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials online or request paper/email copies by February 19, 2026.
Voting matters and shareholder proposals
Election of eleven directors is on the agenda, with board recommendations provided for each nominee.
Advisory vote on the fiscal 2025 compensation for named executive officers is included.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026 is proposed.
Proxy holders may vote on other business that may arise during the meeting.
Board of directors and corporate governance
Eleven director nominees are listed, including Werner Baumann, Frank K. Clyburn, Ellen G. Cooper, and others.
Board recommends voting in favor of all director nominees.
Latest events from Cencora
- Expanded MSO ownership and robust specialty growth drive higher guidance and strategic focus.COR
Leerink Global Healthcare Conference 202610 Mar 2026 - Raised guidance and MSO strategy drive growth, with focus on specialty and de-leveraging.COR
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - All proposals passed, with strong financial growth and major strategic investments announced.COR
AGM 20269 Mar 2026 - Q1 FY2026 revenue up 5.5% to $85.9B; adjusted EPS rose 9.4% to $4.08.COR
Q1 20264 Feb 2026 - Q3 revenue up 10.9% to $74.2B; adjusted EPS up 14.4%; FY2024 guidance raised.COR
Q3 20242 Feb 2026 - Strong financial results, Board refreshment, and robust governance mark fiscal 2025.COR
Proxy Filing22 Jan 2026 - 2024 EPS guidance raised; 2025 growth to slow as COVID impact normalizes, but core business remains strong.COR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - 2024 guidance increased; 2025 growth to slow as COVID impact fades, with specialty and biosimilars leading future gains.COR
Wells Fargo 2024 Healthcare Conference22 Jan 2026 - 2024 guidance raised; 2025 outlook cautious amid COVID normalization and specialty focus.COR
Baird's 2024 Global Healthcare Conference20 Jan 2026